Surface Oncology Inc   (SURF)
Other Ticker:  
Price: $1.0700 $-0.01 -0.926%
Day's High: $1.09 Week Perf: 0.00
Day's Low: $ 1.01 30 Day Perf: 12.56 %
Volume (M): 1,510 52 Wk High: $ 1.12
Volume (M$): $ 1,616 52 Wk Avg: $0.79
Open: $1.06 52 Wk Low: $0.56

 Market Capitalization (Millions $) 65
 Shares Outstanding (Millions) 61
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -93
 Cash Flow (TTM) (Millions $) -62
 Capital Exp. (TTM) (Millions $) 0

Surface Oncology Inc
Surface Oncology Inc. is a biotechnology company that specializes in the development of cancer immunotherapies. The company's primary focus is on the discovery and development of novel antibody-based treatments for various types of cancer. Surface Oncology aims to leverage the body's immune system to fight cancer by targeting specific immune checkpoints and pathways involved in tumor growth and suppression. The company's pipeline includes multiple candidates currently in preclinical and clinical development stages, with a focus on developing therapies with the potential to improve patient outcomes.

   Company Address: 50 Hampshire Street Cambridge 2139 MA
   Company Phone Number: 714-4096   Stock Exchange / Ticker: NASDAQ SURF
   SURF is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Surface Oncology Inc

Surface Oncology Inc Experiences Escalating Losses Amidst Business Setback in Unveiled Fiscal Span Ending June 2023

During the ongoing fiscal April to June 2023 earnings cycle, various businesses have been sharing their financial results. Among them, several corporations in the Biotechnology & Pharmaceuticals industry have recently disclosed their numbers. One such company, Surface Oncology Inc (SURF), has reported an operating loss of $-25.641 million for the second quarter of 2023. While the top-line figures are yet to be announced, it is essential to analyze the company's current performance in the context of previous years.
Current Performance Analysis:
Surface Oncology Inc's operating loss of $-25.641 million in Q2 2023 shows a minor increase compared to the operating loss of $-24.624 million in the same period of 2022. It is worth noting that the emerging growth firm also experienced an extended net loss of $-28.192 million, compared to $-25.213 million from the previous year within the same time frame.

Surface Oncology Inc

Surface Oncology Inc Continues to Struggle Financially, Records No Revenue Growth in Q1 2023

Investors beware, Surface Oncology Inc's financial performance has taken a turn for the worse. The company recorded a staggering deficit per stock of $-0.33 for the financial span ending March 31, 2023. This is a significant drop from the previous year's earnings of $0.13 per share. Furthermore, the company's deficit has grown from $-0.29 per share from the previous financial reporting period. This is a clear indication that the company is facing serious financial challenges.
To compound matters, Surface Oncology Inc's revenue remained unchanged at $0.00 million compared to the $30.00 million recorded in the comparable financial reporting period a year before. While the sequentially revenue advanced from $0.00 million, the overall lack of revenue growth for the company is alarming. With no signs of improvement in revenue, this is a clear indication that Surface Oncology Inc is struggling to make sales and generate revenue.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com